Sussex Cardiac Center, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
Division of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.
Catheter Cardiovasc Interv. 2021 Mar;97(4):E552-E559. doi: 10.1002/ccd.29157. Epub 2020 Aug 11.
We sought to identify baseline demographics and procedural factors that might independently predict in-hospital stroke following transcatheter aortic valve implantation (TAVI).
Stroke is a recognized, albeit infrequent, complication of TAVI. Established predictors of procedure-related in-hospital stroke; however, remain poorly defined.
We conducted an observational cohort analysis of the multicenter UK TAVI registry. The primary outcome measure was the incidence of in-hospital stroke.
A total of 8,652 TAVI procedures were performed from 2007 to 2015. There were 205 in-hospital strokes reported by participating centers equivalent to an overall stroke incidence of 2.4%. Univariate analysis showed that the implantation of balloon-expandable valves caused significantly fewer strokes (balloon-expandable 96/4,613 [2.08%] vs. self-expandable 95/3,272 [2.90%]; p = .020). After multivariable analysis, prior cerebrovascular disease (CVD) (odds ratio [OR] 1.51, 95% confidence interval [CI 1.05-2.17]; p = .03), advanced age at time of operation (OR 1.02 [0.10-1.04]; p = .05), bailout coronary stenting (OR 5.94 [2.03-17.39]; p = .008), and earlier year of procedure (OR 0.93 [0.87-1.00]; p = .04) were associated with an increased in-hospital stroke risk. There was a reduced stroke risk in those who had prior cardiac surgery (OR 0.62 [0.41-0.93]; p = .01) and a first-generation balloon-expandable valve implanted (OR 0.72 [0.53-0.97]; p = .03). In-hospital stroke significantly increased 30-day (OR 5.22 [3.49-7.81]; p < .001) and 1-year mortality (OR 3.21 [2.15-4.78]; p < .001).
In-hospital stroke after TAVI is associated with substantially increased early and late mortality. Factors independently associated with in-hospital stroke were previous CVD, advanced age, no prior cardiac surgery, and deployment of a predominantly first-generation self-expandable transcatheter heart valve.
我们旨在确定可能独立预测经导管主动脉瓣植入术(TAVI)后院内卒中的基线人口统计学和程序因素。
卒中是 TAVI 公认的、但罕见的并发症。然而,与手术相关的院内卒中的既定预测因素仍定义不明确。
我们对英国多中心 TAVI 注册中心进行了一项观察性队列分析。主要观察指标为院内卒中的发生率。
2007 年至 2015 年共进行了 8652 例 TAVI 手术。由参与中心报告的院内卒中共有 205 例,总体卒中发生率为 2.4%。单因素分析显示,球囊扩张瓣膜的植入导致的卒中明显较少(球囊扩张瓣膜 96/4613[2.08%] vs. 自扩张瓣膜 95/3272[2.90%];p=0.020)。多变量分析后,既往脑血管疾病(CVD)(比值比[OR]1.51,95%置信区间[CI]1.05-2.17;p=0.03)、手术时年龄较大(OR 1.02[0.10-1.04];p=0.05)、紧急冠状动脉支架置入术(OR 5.94[2.03-17.39];p=0.008)和较早的手术年份(OR 0.93[0.87-1.00];p=0.04)与院内卒中风险增加相关。既往心脏手术(OR 0.62[0.41-0.93];p=0.01)和植入第一代球囊扩张瓣膜(OR 0.72[0.53-0.97];p=0.03)的患者卒中风险降低。院内卒中显著增加了 30 天(OR 5.22[3.49-7.81];p<0.001)和 1 年死亡率(OR 3.21[2.15-4.78];p<0.001)。
TAVI 术后院内卒中与早期和晚期死亡率显著增加相关。与院内卒中独立相关的因素包括既往 CVD、年龄较大、无既往心脏手术和植入主要为第一代自扩张经导管心脏瓣膜。